Kidney Cancer: Now Available in a New Flavor

The role of the von Hippel-Lindau tumor suppressor protein (pVHL) in kidney cancer has provided a rationale for treating this disease with hypoxia-inducible factor (HIF) antagonists. In this issue, Simon and coworkers show that the molecular signature of VHL−/− kidney cancers is profoundly influenced by whether they produce both HIF2α and HIF1α or HIF2α alone.